Skip to content
CompoundSci
All peptides
Research vial labelled Kisspeptin-10, a Growth hormone secretagogue peptide studied in preclinical and clinical literature

Kisspeptin-10

The file here is mostly preclinical work plus clinic and community practice, not registrational trials.

Upstream of the entire reproductive hormone axis. Continuous exposure desensitises the receptor and does the opposite of what people expect.

General profile

Class
Growth hormone secretagogue
Evidence
Mixed or moderate evidence
Studied dose range
0.1–1 mcg/kg in trial protocols
Frequency in protocols
Intermittent, per study design
Route
Subcutaneous
Half life
~4 minutes
Reconstitution
2 mL bacteriostatic water per 5 mg vial
Storage
Refrigerated, ~30 days

Timing and cycling in the literature

Usually dosed in the morning window

Two to three times weekly

Continuous exposure desensitises the receptor, so study protocols keep dosing intermittent rather than daily.

Reported cycle: 4 weeks on, 4 weeks off

Study use is intermittent and short because the receptor desensitises quickly under sustained exposure.

Watch for: Any change in reproductive hormone symptoms. This sits upstream of the whole axis.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

No named pair conflicts are on file for this compound. That is missing data, not clearance: with no compatibility data the default is separate syringes, and you still introduce one new compound at a time.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how Kisspeptin-10 fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed human efficacy trial that establishes a dose for the use people are chasing.

Open questions: Treat published dosing as observed practice, not a validated protocol.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature